Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 17/20 | 0.75 |
| ▸ | TACR2 | P21452 | 5/20 | 0.63 |
| ▸ | TACR3 | P29371 | 5/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.63 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.63 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5945421 | 0.91 | TRPV4 (0.67) | TRPV4TACR2TACR3KCNH2CACNA1C | |
| SCHEMBL2373330 | 0.91 | TRPV4 (0.72) | TRPV4TACR2TACR3KCNH2CACNA1C | |
| SCHEMBL5945326 | 0.90 | TRPV4 (0.66) | TRPV4TACR2TACR3KCNH2CACNA1C | |
| SCHEMBL5443753 | 0.90 | TRPV4 (0.64) | TRPV4TACR2TACR3KCNH2CACNA1C | |
| Hydrochloric Acid SCHEMBL2372824 | 0.90 | TRPV4 (0.80) | TRPV4TACR2TACR3KCNH2CACNA1C | |
| Hydrochloric Acid SCHEMBL5733490 | 0.90 | TRPV4 (0.71) | TRPV4TACR2TACR3KCNH2CACNA1C | |
| SCHEMBL5945443 | 0.86 | TACR2 (0.85) | TRPV4TACR2TACR3KCNH2CACNA1C | |
| SCHEMBL2372248 | 0.85 | TRPV4 (0.70) | TRPV4TACR2TACR3KCNH2CACNA1C | |
| SCHEMBL5448374 | 0.83 | TRPV4 (0.59) | TRPV4TACR2TACR3KCNH2CACNA1C | |
| SCHEMBL6428018 | 0.83 | TRPV4 (0.70) | TRPV4TACR2TACR3KCNH2CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161647-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 and NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE S.P.A. | 2007-07-12 | — | — | US | claimed |
| US-20050182093-A1 | Novel compounds | GLAXOSMITHKLINE S.P.A. | 2005-08-18 | — | — | US | claimed |
| US-20050176762-A1 | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | GLAXOSMITHKLINE SPA | 2005-08-11 | — | — | US | claimed |
| US-20040152730-A1 | Novel compounds | SMITHKLINE BEECHAM S.P.A. (IT) | 2004-08-05 | — | — | US | claimed |
| US-20040152726-A1 | Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists | SMITHKLINE BEECHAM S.P.A. (IT) | 2004-08-05 | — | — | US | claimed |
| US-20070161647-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 and NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE S.P.A. | 2007-07-12 | — | — | US | disclosed |
| US-20060161004-A1 | Novel compounds | GLAXOSMITHKLINE SPA | 2006-07-20 | — | — | US | disclosed |
| US-20050182093-A1 | Novel compounds | GLAXOSMITHKLINE S.P.A. | 2005-08-18 | — | — | US | disclosed |
| US-20050176762-A1 | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | GLAXOSMITHKLINE SPA | 2005-08-11 | — | — | US | disclosed |
| US-20050070574-A1 | Novel compounds | GLAXOSMITHKLINE SPA AND LABORATOIRE | 2005-03-31 | — | — | US | disclosed |
| US-20040152730-A1 | Novel compounds | SMITHKLINE BEECHAM S.P.A. (IT) | 2004-08-05 | — | — | US | disclosed |
| US-20040152726-A1 | Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists | SMITHKLINE BEECHAM S.P.A. (IT) | 2004-08-05 | — | — | US | disclosed |
| US-20040102633-A1 | Novel compounds | GLAXOSMITHKLINE S.P.A. (IT) | 2004-05-27 | — | — | US | disclosed |
| EP-1377567-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | GlaxoSmithKline S.p.A. (IT) | 2004-01-07 | — | — | EP | disclosed |
| WO-2002083663-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE S.P.A. (IT) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070574-A1 | Novel compounds | NR1H3, NR1H2, CNR1 | TRPV4 1565/4885TACR2 52/4885TACR3 301/4885 |
| US-20050182093-A1 | Novel compounds | SLC10A1, AVPR2, REN | TRPV4 1507/4885TACR2 1103/4885TACR3 3323/4885 |
| US-20040152726-A1 | Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists | KCNH2, KCNH3, KCNJ8 | TRPV4 1268/4885TACR2 56/4885TACR3 149/4885 |
| US-20060161004-A1 | Novel compounds | SLC10A1, ABCB11, AQP1 | TRPV4 1307/4885TACR2 862/4885TACR3 2824/4885 |
| US-20070161647-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 and NK-2 RECEPTOR ANTAGONISTS | KCNQ3, KCNK3, KCNK2 | TRPV4 395/4885TACR2 22/4885TACR3 45/4885 |
| US-20040102633-A1 | Novel compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, NR1H3 | TRPV4 2393/4885TACR2 155/4885TACR3 1027/4885 |
| US-20040152730-A1 | Novel compounds | SLC10A1, AVPR2, REN | TRPV4 1507/4885TACR2 1103/4885TACR3 3323/4885 |
| US-20050176762-A1 | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | KCNQ3, KCNK3, KCNK2 | TRPV4 395/4885TACR2 22/4885TACR3 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.